Hypochlorous Acid as a Potential Postsurgical Antimicrobial Agent in Periodontitis: A Randomized, Controlled, Non-Inferiority Trial

Julio Cesar Plata ^1,2, David Díaz-Báez ³ , Nathaly Andrea Delgadillo ³ , Diana Marcela Castillo ³ , Yormaris Castillo ³ , Claudia Patricia Hurtado ² , Yineth Neuta ³ , Justo Leonardo Calderón ³ and Gloria Inés Lafaurie ^3,*

1 Master’s Program in Dental Sciences, School of Dentistry, Universidad El Bosque, Bogotá P.O. Box 110121, Colombia; 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。

2 School of Dentistry, Universidad Cooperativa de Colombia, Bucaramanga P.O. Box 680001, Colombia; 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。

3 Unit of Oral Basic Investigation-UIBO, School of Dentistry, Universidad El Bosque, Bogotá P.O. Box 110121, Colombia; 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。 (D.D.-B.); 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。 (N.A.D.); 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。 (D.M.C.); 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。 (Y.C.); 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。 (Y.N.); 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。 (J.L.C.)

* Correspondence: 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。

Abstract: Background: Hypochlorous acid (HOCl) is an antimicrobial agent with high affinity to Gram-negative bacteria of the subgingival biofilm. It could have an equivalent or no inferiority effect to chlorhexidine (CHX) to avoid recolonization of these microorganisms after the post-surgical period. Objective: The objective is to compare the reduction of plaque index (PI), gingival index (GI), pocket depth (PD), gain of clinical attachment level (CAL), and bacterial recolonization of periodontopathic microorganisms in subgingival biofilm at 7, 21, and 90 days after Open Flap Debridement (OFD) under two antimicrobial protocols: (A) HOCl 0.05% followed by HOCl 0.025% and (B) CHX 0.2%/CHX 0.12% used per 21 days without regular oral hygiene during the post-surgical period. Material and methods: A no-inferiority randomized controlled trial was carried out. Thirty-two patients were randomly divided to receive each antiplaque protocol after OFD in patients with periodontitis. Clinical indexes and bacterial recolonization were assessed using qPCR for up to 90 days. Data were analyzed using repeated measures ANOVA, mixed effects models adjusted for treatment, time, and the Chi-squared/Fisher test. A no-inferiority analysis was also performed using the Hodges–Lehmann hypothesis test for non-inferiority. Results: HOCl was not inferior to CHX in reducing PI. Both groups showed a comparable reduction of recolonization for Porphyromonas gingivalis, Tannerella forsythia, and Eubacterium nodatum. However, the HOCl protocol was non-inferior to the CHX protocol for Treponema denticola and Aggregatibacter actinomicetemcomitans. Conclusions: HOCl improved periodontal healing. HOCl showed an impact in reducing the recolonization of periodontopathic bacteria in the postoperative period.

Keywords: chlorhexidine; antiplaque; bacterial recolonization; hypochlorous acid

Skin preparation for preventing infection following caesarean section

Diah R Hadiati¹, Mohammad Hakimi¹, Detty S Nurdiati ², Yuko Masuzawa³, Katharina da Silva Lopes ⁴, Erika Ota⁵

¹Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia. ²Department of Obstetrics and Gynaecology, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia. ³Department of Health Informatics, Graduate

School of Medicine/School of Public Health, Kyoto University, Kyoto, Japan. ⁴Graduate School of Public Health, St. Luke's International University, Tokyo, Japan. ⁵Global Health Nursing, Graduate School of Nursing Science, St. Luke's International University, Tokyo, Japan

Contact: Diah R Hadiati, 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。.

Editorial group: Cochrane Pregnancy and Childbirth Group.

Publication status and date: New search for studies and content updated (no change to conclusions), published in Issue 6, 2020.

Citation: Hadiati DR, Hakimi M, Nurdiati DS, Masuzawa Y, da Silva Lopes K, Ota E. Skin preparation for preventing infection following caesarean section. Cochrane Database of Systematic Reviews 2020, Issue 6. Art. No.: CD007462. DOI: 10.1002/14651858.CD007462.pub5. Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Topical antibiotics for preventing surgical site infection in wounds healing by primary intention

Clare F Heal ^1,2, Jennifer L Banks ³, Phoebe D Lepper ³, Evangelos Kontopantelis ⁴, Mieke L van Driel ⁵

¹General Practice and Rural Medicine, James Cook University, Mackay, Australia. ²Anton Breinl Research Centre for Health Systems Strengthening, Townsville, Australia. ³School of Medicine and Dentistry, James Cook University, Mackay, Australia. ⁴Centre for Health Informatics, Institute of Population Health, The University of Manchester, Manchester, UK. ⁵Discipline of General Practice, School of Medicine, The University of Queensland, Brisbane, Australia

Contact: Clare F Heal, General Practice and Rural Medicine, James Cook University, Mackay Base Hospital, Bridge Road, Mackay, Queensland, 4740, Australia. 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。.

Editorial group: Cochrane Wounds Group.

Publication status and date: New, published in Issue 11, 2016.

Citation: Heal CF, Banks JL, Lepper PD, Kontopantelis E, van Driel ML. Topical antibiotics for preventing surgical site infection in wounds healing by primary intention. Cochrane Database of Systematic Reviews 2016, Issue 11. Art. No.: CD011426. DOI: 10.1002/14651858.CD011426.pub2.

Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

０.０１％次氯酸在白内障超声乳化术前应用的安全性和有 效性

王雨蒙，陆秋辰，赵颖奕，史灿灿，李明新，王贺

ADJUNCTIVE DEBRIDEMENT WITH HYPOCHLOROUS ACID LEADS TO A HEALING TRAJECTORY OF COMPLEX WOUNDS IN CHILDREN

Ferne T. Elsass, MSN, RN, CPN, CWON; Clinical Practice and Education Specialist of Wound and Ostomy, Children’s Hospital of The King’s Daughters, Norfolk, VA 23507

Hypochlorous Acid (HOCl) as a Promising Respiratory Antiseptic

Michael Winter ¹ , Dirk Boecker ² and Wilfried Posch ^3,*

1 Team Winter Kompetenztraining, 1030 Vienna, Austria; 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。

2 TOTO Consulting LLC, Campbell, CA 95080, USA; 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。

3 Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Schöpfstrasse 41/R311,6020 Innsbruck, Austria

*Correspondence: 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。; Tel.: +43-512-9003-70706

Abstract

The COVID-19 pandemic has inflicted unprecedented pressure on communities and health-care systems around the world. An outstandingly broad and intensive investigation of possible therapeutic interventions is currently taking place to prevent similar future threats to the global population. Investigating the related mechanisms of action is often complex and time consuming. Moreover, research on biochemical interactions of new drugs involves a considerable amount of effort, consequently bearing inherent financial and operational risks for pharmaceutical companies. An interesting approach to counteract colonization and infection is the concept of antiseptic treatment in vivo. Antiseptics are cost-effective and globally accessible, due to their ease of production, transportation and handling. A broad spectrum of active agents with different properties is readily available. One of these substances is hypochlorous acid (HOCl), which is also a naturally occurring biocidal agent and as such part of the innate immune system. Its successful history of medical use in wound treatment, combined with low cytotoxicity and documented efficacy against various pathogens, suggests that HOCl might be an effective agent for treating the respiratory mucosa. This could potentially enable therapeutic inhalation for combating bacterial infections and viral pathogens such as human respiratory syncytial, influenza, and SARS-CoV-2 viruses, which will be discussed in the present article.

Keywords: HOCl; respiratory infection; antiseptic; antimicrobial treatment; RSV; influenza; COVID-19; SARS-CoV-2